Our history
OncoDiag is a French biotechnology company based in Normandy at one hour
from Paris and Rouen cities. The company is focused on developing of non-invasive
diagnostic tests for early detection of cancers. Its lead product the Urodiag® (CE-IVD) is a urine-based lab test for the surveillance of bladder cancer. The company's pipeline also includes the ProstaScore® test to predict non-evolutive localized prostate cancer and the Colodiag® test for the screening of colorectal cancer.
The management is assumed by a highly qualified team, with complementary expertise and supported by a scientific advisory board representative of the health sector.
Executive management
Claude Hennion, PhD
President and CEO
Dr. Claude Hennion is co-founder of OncoDiag and has more than 30 years
of experience in the management of start-up and valorisation of innovation. Claude has a Ph.D. in Physics from Paris VI University.
|
Jean-Pierre Roperch, PhD
Director of Research & Development
Dr. Jean-Pierre Roperch is co-founder of OncoDiag and has more than 30 years of experience developing "In Vitro" Diagnostic in oncology. Jean-Pierre has a Ph.D. in Cellular and Molecular Biology from Paris VI University. |
Scientific advisory board
Pr. Yann NeuzilletUrologist, Foch hospital, Suresnes (France), Vice-President of the French Association of Urology (AFU)
Dr. Géraldine PignotUrologist, Paoli-Calmettes institute, Marseille (France)
Pr. Morgan RouprêtUrologist, Pitié-Salpétrière hospital, Paris (France)
|
|
|
|
|
|
|
|
